ReviewCurrent pharmaceutical biotechnology2024

Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor Microenvironment.

Yiqing Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.